Drug intelligence / Profile preview

68Ga-NOTA-MAL-Cys39-exendin-4

Development stage
Phase 1
Lead developer
Nanjing First Hospital
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
Administration
Intravenous
01

Overview

68Ga-NOTA-MAL-Cys39-exendin-4 is a radiolabeled peptide tracer designed for positron emission tomography (PET) imaging of glucagon-like peptide-1 receptor (GLP-1R) positive tumors, particularly insulinoma. The tracer consists of exendin-4, a GLP-1R agonist, conjugated with NOTA-MAL at the Cys39 position and radiolabeled with gallium-68. Upon administration, the exendin-4 moiety binds to GLP-1R, allowing detection of GLP-1R-expressing tissues using PET/CT imaging. In preclinical studies, it demonstrated high tumor uptake with good contrast to background, favorable biodistribution, and high affinity to islet tumor cells. The tracer shows potential for the detection and localization of insulinoma and other GLP-1R positive tumors.

Other names
Gallium-68 NOTA-MAL-Cys39-exendin-4Gallium68 NOTA-MAL-Cys39-exendin-4Gallium 68 NOTA-MAL-Cys39-exendin-4
02

Targets

Beyond the preview

Go deeper on 68Ga-NOTA-MAL-Cys39-exendin-4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 68Ga-NOTA-MAL-Cys39-exendin-4.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call